The dexamethasone suppression test and CSF-5-HIAA in relation to suicidality and depression in suicide attempters

European Psychiatry

Volumn 18, Issue 4, 2003, Pages 166-171

  Westrin, Åsa ^a   Niméus, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Attempted; Depressive disorder; Pituitary adrenal system; Serotonin; Suicide; Suicide Assessment Scale

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; HYDROCORTISONE;

5 HYDROXYINDOLEACETIC ACID BRAIN LEVEL; ADULT; ARTICLE; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; FEMALE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SEROTONINERGIC SYSTEM; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT;

EID: 0037869556     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(03)00044-0     Document Type: Article

References (33)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington (DC): American Psychiatric Association; 1987.
2. Banki CM, Arato M, Papp Z, Kurcz M. Biochemical markers in suicidal patients. Investigations with cerebrospinal fluid amine metabolites and neuroendocrine tests. J Affective Disorders 1984;6(3-4):341-50.
3. Berger M, Pirke KM, Doerr P, Krieg JC, Von Zerssen D. The limited utility of the dexamethasone suppression test for the diagnostic process in psychiatry. Br J Psychiatry 1984;145:372-82.
4. Brown RP, Mason B, Stoll P, Kocsis J, Stokes PE, et al. Adrenocortical function and suicidal behavior in depressive disorders. Psychiatry Res 1986;17:317-23.
5. Bunney Jr WE, Fawcett J. Possibility of a biochemical test for suicidal patients. Arch Gen Psychiatry 1965;13:232-9.
6. Bunney Jr WE, Fawcett JA, Davis JM, Giffford S. Further evaluation of urinary 17-hydroxycorticoids in suicidal patients. Arch Gen Psychiatry 1969;21(2):138-50 (hydroxycorticosteroids in suicidal pa).
7. Bäckman J, Alling C, Alsén M, Regnéll G, Träskman-Bendz L. Changes of cerebrospinal fluid monoamine metabolites during longterm antidepressant treatment. Eur Neuropsychopharmacol 2000;10: 341-9.
8. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation and clinical utility. Arch Gen Psychiatry 1981;38(1):15-22.
9. Coryell W, Schlesser MA. Suicide and the dexamethasone suppression test in unipolar depression. Am J Psychiatry 1981;138(8): 1120-1.
10. Coryell W, Schlesser M. The dexamethasone suppression test and suicide prediction. Am J Psychiatry 2001(5):748-53 158.
11. Gjerris A, Werdelin L, Gjerris F, Sörensen PS, Rafaelsen OJ, Alling C. CSF-amine metabolites in depression, dementia and controls. Acta Psychiatr Scand 1987;75:619-28.
12. Jones JS, Stein DJ, Stanley B, Guido JR, Winchel R, Stanley M. Negative and depressive symptoms in suicidal schizophrenics. Acta Psychiatr Scand 1994;89(2):81-7.
13. Lester D. The concentration of neurotransmitter metabolites in the cerebrospinal fluid of suicidal individuals: a meta-analysis. Pharmacopsychiatry 1995;28(2):45-50 77-9.
14. Lester D. The dexamethasone suppression test as an indicator of suicide: a meta-analysis. Pharmacopsychiatry 1992;25:226-7.
15. Lopez JF, Akil H, Watson J. Neural circuits mediating stress. Biol Psychiatry 1999;46:1461-71.
16. Lopez JF, Chalmers DT, Little KY, Watson SJ. A.E. Bennett Research Award. Regulation of serotonin 1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology. Biol Psychiatry 1998;43(8):547-73.
17. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
18. Niméus A, Alsén M, Träskman-Bendz L. The Suicide Assessment Scale - an instrument assessing suicide risk of suicide attempters. Eur Psychiatry 2000;15:416-23.
19. Nordström P, Samuelsson M, Åsberg M, Träskman-Bendz L, Åberg-Wistedt A, Nordin C, et al. CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life-Threatening Behav 1994;24(1):1-9.
20. Ostroff R, Giller E, Bonese K, Ebersole E, Harkness L. Neuroendocrine risk factors of suicidal behavior. 10. Am J Psychiatry 1982; 139: 1323-5.
21. Pitchot W, Hartsenne M, Gonzalez Moreno A, Ansseau M. The dexamethasone suppression test in violent suicide attempters with major depression. Biol Psychiatry 1995;37(4):273-4.
22. Roy A. Hypothalamic-pituitary-adrenal axis function and suicidal behavior in depression. Biol Psychiatry 1992;32(9):812-6.
23. Roy A, De Jong J, Linnoila M. Cerebrospinal fluid monoamine metabolites and suicidal behavior n depressed patients. A 5-year follow-up study. Arch Gen Psychiatry 1989;46(7):609-12.
24. Schmidtke A, Fleckenstein P, Beckmann H. The dexamethasone suppression test and suicide attempts. Acta Psychiatr Scand 1989;79(3): 276-82.
25. Secunda SK, Cross CK, Koslow S, Katz MM, Kocsis J, Maas JW, et al. Biochemistry and suicidal behavior in depressed patients. Biol Psychiatry 1986;21(8-9):756-67.
26. Stanley B, Träskman-Bendz L, Stanley M. The Suicide Assessment Scale: a scale evaluating change in suicidal behavior. Psychopharm Bull 1986;1:200-5.
27. Targum SD, Rosén L, Capodanno AE. The dexamethasone suppression test in suicidal patients with unipolar depression. Am J Psychiatry 1983;140(7):877-9.
28. Traskman L, Asberg M, Bertilsson L, Cronholm B, Mellstrom B, Neckers LM, et al. Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression. Clin Pharmacol Ther 1979; 26(5):600-10.
29. Träskman L, Åsberg M, Bertilsson L, Sjöstrand L. Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry 1981; 38:631-6.
30. Träskman-Bendz L, Alling C, Oreland L, Regnéll G, Vinge E, Öhman R. Prediction of suicidal behavior from biologic tests. J Clin Psychopharmacol 1992;12(Suppl 2):S21-26.
31. van Praag HM. Faulty cortisol/serotonin interplay. Psychopathological and biological characterization of a new, hypothetical depression subtype (seCa-depression). Psychiatry Res 1996;65:143-57.
32. Westrin Å, Ekman R, Träskman-Bendz L. High delta sleep-inducing peptide-like immunoreactivity in plasma in suicidal patients with major depressive disorder. Biol Psychiatry 1998;43(10):734-9.
33. Ågren H, Niklasson F. Suicidal potential in depression: focus on CSF monoamine purine metabolites. Psychopharm Bull 1986;22(3): 656-60.